Navigation Links
Watson Promotes Robert Stewart to Executive Vice President, Global Operations

MORRISTOWN, N.J., Aug. 3 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals (NYSE: WPI) today announced that Robert Stewart, who joined the Company in November 2009 as Senior Vice President, Global Operations, has been promoted to Executive Vice President, Global Operations. Mr. Stewart will continue to report to Paul Bisaro, President and Chief Executive Officer of Watson.

Mr. Stewart will assume responsibility for managing Global Generic Research and Development activities, in addition to having responsibility for Global Operations (manufacturing, supply chain, engineering, facilities and EH&S), Global Quality and Regulatory and Global Information Technology.

"This promotion recognizes the contributions Bob and his team have made in integrating the assets, technologies and resources acquired from Arrow and in continuing to maximize the potential of our global supply chain," said Bisaro.  "As a result of this promotion, the three significant components of our business -- Global Generics, Global Brands and Global Operations -- will now be led by Executive Vice Presidents, reporting directly to me.  In addition, moving Generic R&D under Global Operations recognizes that close coordination between R&D and Operations is critical to accelerating speed to market.  Bob will now assume responsibility for ensuring that the process from product development to approval and distribution is seamless and efficient, enhancing our ability to compete in the markets we serve with products that create increased value for our customers and our shareholders."

Mr. Stewart joined Watson following an eight-year career at Abbott Laboratories, where he most recently served as Divisional Vice President, Global Supply Chain.  From 2005 until 2008, he served as Divisional Vice President, Quality Assurance.  Prior to this position, Mr. Stewart was Abbott's Divisional Vice President for U.S./Puerto Rico and Latin America Plant Operations, as well as Director of Operations for Abbott's Whippany, NJ plant.  Prior to Abbott, he worked for Knoll Pharmaceutical Company and Hoffman La-Roche Inc.

About Watson Pharmaceuticals, Inc.

Watson Pharmaceuticals, Inc. is a leading global specialty pharmaceutical company. The Company is engaged in the development and distribution of generic pharmaceuticals and specialized branded pharmaceutical products focused on urology and women's health. Watson has operations in many of the world's established and growing international markets.

For press release and other company information, visit Watson Pharmaceuticals' Web site at

Forward-Looking Statement

Statements contained in this press release that refer to non-historical facts are forward-looking statements that reflect Watson's current perspective of existing information as of the date of this release.  It is important to note that Watson's goals and expectations are not predictions of actual performance. Actual results may differ materially from Watson's current expectations depending upon a number of factors affecting Watson's business. These factors include, among others,  such risks and uncertainties detailed in Watson's periodic public filings with the Securities and Exchange Commission, including but not limited to Watson's annual report on Form 10-K for the year ended December 31,2009 and Watson's quarterly report on Form 10-Q for the period ended March 31, 2010. Except as expressly required by law, Watson disclaims any intent or obligation to update these forward-looking statements.

(Logo: )

(Logo: )

SOURCE Watson Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Watson Confirms Renvela® for Oral Suspension Patent Challenge
2. Watson to Host Conference Call and Webcast to Discuss Second Quarter 2010 Earnings
3. Watson Completes Acquisition of CRINONE® and PROCHIEVE® Product Line and Shares of Columbia Laboratories
4. Watsons Generic Prograf® 5 mg Receives FDA Approval
5. Watson Launches Generic Exelon®
6. Watson Confirms Columbia Laboratories Shareholder Approval of Proposed Acquisition of Progesterone-related Assets
7. Watson to Present at the Wells Fargo Securities 2010 Healthcare Conference
8. Watson Confirms Columbia Laboratories Filing of Definitive Proxy Relating to Watsons Acquisition of U.S. Rights to CRINONE® Progesterone Gel Product Line
9. Watsons Generic VALTREX® 500 mg and 1000 mg Receives FDA Approval
10. Watson Launches Generic Version of LIPITOR® in Canada
11. Watson to Present at the 2010 Citi Investment Research Global Healthcare Conference
Post Your Comments:
(Date:12/1/2015)... --> --> ... by Type of Drug (Monoclonal Antibodies, Interferon-Alpha, Interleukins, Vaccines, (Therapeutic ... Analysis - Global Forecast to 2020", published by MarketsandMarkets, the ... Million by 2020 from USD 40,281.6 Million in 2015, at ... Browse 37 market data T ...
(Date:12/1/2015)... , Dec. 1, 2015 Assurex ... its GeneSight® Psychotropic test giving healthcare providers an expanded ... decisions for patients suffering from depression, anxiety, bipolar ... behavioral health conditions. i . ... --> With the addition of two new ...
(Date:12/1/2015)... , Dec. 1, 2015  Six months of adjunctive ... with type 1 diabetes, according to new research from ... However, it may have a beneficial effect on measures of ... current issue of the Journal of the American Medical ... examining the effect of metformin on overweight and obese adolescents ...
Breaking Medicine Technology:
(Date:12/1/2015)... (PRWEB) , ... December 01, 2015 , ... Dr. Paul ... Vitenas Cosmetic Surgery, has been named by MedEsthetics magazine as the Best Single Physician ... the best among the many elite aesthetic physicians honored by the industry publication. ...
(Date:12/1/2015)... ... December 01, 2015 , ... December 1, 2015 ... of the company’s growing product line of food safety and seafood fraud prevention ... (Oncorhynchus nerka) – allow InstantLabs to offer fast, reliable species identification for the ...
(Date:12/1/2015)... ... ... It’s official: Tattoo taboo is a thing of the past. One in ... whopping one in three aged 18 to 25 is inked). As tattoos transition to ... In fact, RealSelf , the world’s largest community for learning and sharing information ...
(Date:12/1/2015)... ... , ... The importance of volumetric breast density assessment for ... abstracts accepted for presentation here, at the 101st Annual Radiology Society of North ... of Volpara Solutions’ quantitative breast imaging software tools for providing breast imaging and ...
(Date:12/1/2015)... CA (PRWEB) , ... December 01, 2015 , ... ... scale , Visage Imaging Inc. (“Visage”), a wholly owned subsidiary of Pro Medicus ... imaging results enhancements at the Radiological Society of North America (RSNA) 2015 annual ...
Breaking Medicine News(10 mins):